Lee Hambright
Stock Analyst at Bernstein
(3.57)
# 887
Out of 4,738 analysts
22
Total ratings
81.25%
Success rate
13.76%
Average return
Main Sectors:
Stocks Rated by Lee Hambright
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MDT Medtronic | Maintains: Outperform | $96 → $97 | $87.84 | +10.43% | 2 | Nov 20, 2024 | |
| PODD Insulet | Initiates: Outperform | $300 | $278.89 | +7.57% | 1 | Nov 6, 2024 | |
| TNDM Tandem Diabetes Care | Initiates: Outperform | $42 | $35.00 | +20.00% | 1 | Nov 6, 2024 | |
| DXCM DexCom | Maintains: Outperform | $82 → $86 | $87.09 | -1.25% | 2 | Oct 25, 2024 | |
| BSX Boston Scientific | Maintains: Outperform | $92 → $100 | $100.31 | -0.31% | 1 | Oct 24, 2024 | |
| ABT Abbott Laboratories | Maintains: Outperform | $133 → $138 | $117.78 | +17.17% | 2 | Oct 17, 2024 | |
| ISRG Intuitive Surgical | Maintains: Outperform | $350 → $365 | $610.45 | -40.21% | 2 | May 31, 2023 | |
| ZBH Zimmer Biomet Holdings | Maintains: Market Perform | $136 → $152 | $109.72 | +38.53% | 1 | May 3, 2023 | |
| JNJ Johnson & Johnson | Downgrades: Market Perform | $183 | $145.27 | +25.97% | 4 | Mar 16, 2022 | |
| SYK Stryker | Upgrades: Outperform | $288 → $295 | $390.49 | -24.45% | 3 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $132 → $135 | $69.04 | +95.54% | 3 | Mar 16, 2022 |
Medtronic
Nov 20, 2024
Maintains: Outperform
Price Target: $96 → $97
Current: $87.84
Upside: +10.43%
Insulet
Nov 6, 2024
Initiates: Outperform
Price Target: $300
Current: $278.89
Upside: +7.57%
Tandem Diabetes Care
Nov 6, 2024
Initiates: Outperform
Price Target: $42
Current: $35.00
Upside: +20.00%
DexCom
Oct 25, 2024
Maintains: Outperform
Price Target: $82 → $86
Current: $87.09
Upside: -1.25%
Boston Scientific
Oct 24, 2024
Maintains: Outperform
Price Target: $92 → $100
Current: $100.31
Upside: -0.31%
Abbott Laboratories
Oct 17, 2024
Maintains: Outperform
Price Target: $133 → $138
Current: $117.78
Upside: +17.17%
Intuitive Surgical
May 31, 2023
Maintains: Outperform
Price Target: $350 → $365
Current: $610.45
Upside: -40.21%
Zimmer Biomet Holdings
May 3, 2023
Maintains: Market Perform
Price Target: $136 → $152
Current: $109.72
Upside: +38.53%
Johnson & Johnson
Mar 16, 2022
Downgrades: Market Perform
Price Target: $183
Current: $145.27
Upside: +25.97%
Stryker
Mar 16, 2022
Upgrades: Outperform
Price Target: $288 → $295
Current: $390.49
Upside: -24.45%
Mar 16, 2022
Upgrades: Outperform
Price Target: $132 → $135
Current: $69.04
Upside: +95.54%